Alnylam Pharmaceuticals, Inc. last reported quarterly results on Oct 29, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $1.5 billion (+16.7% year over year) and diluted EPS of $15.72. It usually reports 12–30 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–30 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 29, 2026
29 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
1,458
+16.7%
|
2,167
+640.5%
|
15.72
+634.6%
|
|
Jul 30, 2026
30 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
1,291
+66.9%
|
164
+327.7%
|
1.21
+320.0%
|
|
Apr 30, 2026
30 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
—
|
—
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
1,097
+84.9%
|
112
+233.2%
|
0.82
+226.2%
|
|
Oct 30, 2025
30 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
1,249
+149.3%
|
293
+362.3%
|
2.14
+346.0%
|
|
Jul 31, 2025
31 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
774
+17.3%
|
-72
-327.7%
|
-0.55
-323.1%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
593
+34.9%
|
-84
+39.2%
|
-0.65
+40.9%
|
|
Jan 8, 2024
8 days after quarter end
|
—
ended Dec 31, 2023
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALNY (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1178670
- Former names
- ALNYLAM PHARMACEUTICALS INC (until Jul 2, 2004)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.